Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple Myeloma

Video

Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.

Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.

Clinical Pearls:

  • The randomized, phase III study enrolled 1,624 patients and had three arms
  • The results showed that the cocktail of Revlimid plus dexamethasone was superior to MPT
  • These data will be sufficient to lead to the approval to Revlimid plus dexamethasone
  • Revlimid plus dexamethasone is used in the United States off-label, even though it is not approved in that setting
Recent Videos
Related Content
Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer

Dr Galsky on Durvalumab's FDA Approval in Muscle-Invasive Bladder Cancer

Jordyn Sava
April 3rd 2025
Article

Matt Galsky, MD, delved into the recent approval of a perioperative durvalumab regimen in muscle-invasive bladder cancer.

Read More

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM

Binod Dhakal, MD, MS;Jordyn Sava
June 14th 2024
Podcast

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Listen

Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Neoadjuvant TAR-200 Plus Cetrelimab Safe in Cisplatin-Ineligible MIBC

Jordyn Sava
April 1st 2025
Article

Neal Shore, MD, FACS, discussed findings from the SunRISe-4 trial of TAR-200 and cetrelimab in muscle-invasive bladder cancer.

Read More

Advancing Myeloma Treatment With Blood-Based MRD Testing

Advancing Myeloma Treatment With Blood-Based MRD Testing

Jordyn Sava;Ben Derman, MD
February 15th 2024
Podcast

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

Listen

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Cema-Cel Advances CAR T Therapy for LBCL in ALPHA Trials

Jordyn Sava
March 28th 2025
Article

Frederick L. Locke, MD, discussed cema-cel's safety, efficacy, and potential for treating large B-cell lymphoma in earlier lines in the ALPHA trials.

Read More

Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma

Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma

Targeted Oncology Staff
March 25th 2025
Article

During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory multiple myeloma.

Read More